The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
Irinotecan and temozolomide led to inferior clinical outcomes for patients with recurrent and primary refractory Ewing sarcoma, a multiarm trial found.
Patients with advanced sarcoma who developed immune-related adverse events after immune checkpoint blockade were more likely to have a clinical benefit.
Binimetinib plus imatinib in the frontline setting appeared to improve outcomes for patients with advanced gastrointestinal stromal tumor, warranting further study.
A phase 2 trial is under way to evaluate an investigational autologous T-cell product in patients with advanced synovial sarcoma as well as other tumor types.
A single-arm phase II clinical trial is underway to evaluate temozolomide and olaparib as a treatment combination for patients with advanced uterine leiomyosarcoma.
This indication was granted accelerated approval based on overall response rate (ORR) and continued approval may be contingent upon confirmatory trial results.
